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ABSTRACT
Objective: To assess in an observational study whether serum peptide antibody reactivities may
distinguish aquaporin-4 (AQP4) antibody (Ab)–positive and -negative neuromyelitis optica spec-
trum disorders (NMOSD) and relapsing-remitting multiple sclerosis (RRMS).
Methods: We screened 8,700 peptides that included human and viral antigens of potential rele-
vance for inflammatory demyelinating diseases and random peptides with pooled sera from differ-
ent patient groups and healthy controls to set up a customized microarray with 700 peptides.
With this microarray, we tested sera from 66 patients with AQP4-Ab-positive (n 5 16) and
AQP4-Ab-negative (n 5 19) NMOSD, RRMS (n 5 11), and healthy controls (n 5 20).
Results: Differential peptide reactivities distinguished NMOSD subgroups from RRMS in 80% of
patients. However, the 2 NMOSD subgroups were not well-discriminated, although those pa-
tients are clearly separated by their antibody reactivities against AQP4 in cell-based assays. Ele-
vated reactivities to myelin and Epstein-Barr virus peptides were present in RRMS and to AQP4
and AQP1 peptides in AQP4-Ab-positive NMOSD.
Conclusions: While AQP4-Ab-positive and -negative NMOSD subgroups are not well-
discriminated by peptide antibody reactivities, our findings suggest that peptide antibody reactiv-
ities may have the potential to distinguish between both NMOSD subgroups and MS. Future
studies should thus concentrate on evaluating peptide antibody reactivities for the differentiation
of AQP4-Ab-negative NMOSD and MS. Neurol Neuroimmunol Neuroinflamm 2016;3:e204; doi:
10.1212/NXI.0000000000000204
GLOSSARY
AQP4-Ab 5 aquaporin-4 antibody; EBNA-1 5 Epstein-Barr nuclear antigen-1; EBV 5 Epstein-Barr virus; IgG 5 immuno-
globulin G; MOG 5 myelin oligodendrocyte glycoprotein; MS 5 multiple sclerosis; NMO 5 neuromyelitis optica; NMOSD 5
neuromyelitis optica spectrum disorders; RRMS 5 relapsing-remitting multiple sclerosis.
Neuromyelitis optica (NMO) is a rare, often severe, autoimmune CNS disease that predomi-
nantly targets the optic nerves and the spinal cord. The discovery of a specific serum biomarker,
an autoantibody directed against the astrocytic water channel aquaporin-4 (AQP4-Ab),1
strongly suggests that NMO is distinct from classic multiple sclerosis (MS), and has also led
to the recognition of an expanded spectrum of clinical manifestations of NMO, termed NMO
spectrum disorders (NMOSD).2,3
About 20%–40% of patients with clinical signs of NMOSD do not have AQP4-Abs and the
underlying pathogenesis in these patients is unclear.4 The recent detection of anti–myelin oli-
godendrocyte glycoprotein (MOG) antibodies in some of the AQP4-Ab-seronegative patients
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with clinical signs of NMOSD suggests that
autoantigens other than AQP4 may play a role
in this condition.5
The most important differential diagnosis
of NMOSD remains MS. Indeed, initially
misdiagnosing NMOSD as MS occurs fre-
quently (40%).6 A correct distinction between
NMOSD andMS is crucial as the prognosis in
NMOSD is usually worse, and some MS ther-
apies such as interferon-b, natalizumab, or fin-
golimod are probably ineffective or harmful in
NMOSD.7
Therefore, the identification of biomarkers
to differentiate between NMOSD and MS is
highly desirable for improved diagnosis and
appropriate treatment. Peptide microarrays
were previously used to distinguish between
different disease courses and neuropathologic
subtypes of MS, as well as acute disseminated
encephalomyelitis and relapsing-remitting MS
(RRMS).8,9 The aim of this study was to clarify
whether serum peptide antibody reactivities
may distinguish AQP4-Ab-positive and -negative
NMOSD and RRMS.
METHODS We developed a customized peptide microarray
containing more than 700 peptides that represent human and
viral antigens potentially relevant for inflammatory demyelinating
CNS diseases as well as random peptides. With this selection mi-
croarray, we tested sera from 66 patients with AQP4-Ab-positive
and AQP4-Ab-negative NMOSD, RRMS, and healthy controls.
Standard protocol approvals, registrations, and patient
consent. The study was approved by the institutional review
boards of the Charité Universitätsmedizin Berlin (EA1/182/10
and EA1/131/09), the University of Düsseldorf (3419), the Uni-
versity of Heidelberg (S-405/2008), and the University Medical
Center Göttingen (19/09/10). All participants gave written
informed consent.
Patients and healthy controls. Blood samples included 2 non-
overlapping sets of sera. For a preselection of peptides with the
antigen microarray and mimotope microarray (see below), we
analyzed serum pools from 4 patients each with NMOSD nega-
tive for AQP4-Abs (AQP4Ab2NMOSD), NMOSD positive for
AQP4-Abs (AQP4Ab1 NMOSD), MS with histopathologically
defined immunopatterns of demyelination I, II, and III,10 and
healthy controls. For the final microarray analysis (selection
microarray, see below), blood samples were obtained from
patients with AQP4Ab2 NMOSD (n 5 19), patients with
AQP4Ab1 NMOSD (n 5 16), patients with RRMS (n 5 11),
and healthy controls (n 5 20). All available patients with AQP42
NMOSD were included in the study as well as patients from other
groups randomly selected with similar group size. Patients with
NMOSD were recruited at the Department of Neurology and
NeuroCure Clinical Research Center, Charité-Universitätsmedizin
Berlin, the Department of Neurology, University of Heidelberg,
and the Department of Neurology, Heinrich-Heine University
Düsseldorf. Patients with MS with histopathologically defined
immune patterns were recruited at the Department of
Neuropathology, University Medical Center Göttingen, and
patients with RRMS (non-biopsied) as well as healthy controls at
the Department of Neurology and NeuroCure Clinical Research
Centre, Charité-Universitätsmedizin Berlin. The group of patients
with AQP4Ab1 and AQP4Ab2 included patients diagnosed with
NMOSD according to the revised Wingerchuk 2006 criteria,11 as
well as patients with NMOSD.12 RRMS was diagnosed according to
the revised McDonald criteria.13 All sera analyzed with the selection
microarray were tested by cell-based assays for antibodies to AQP414
and to MOG (MOG-Abs) (EUROIMMUN, Lübeck, Germany).
AQP4-Abs were present in sera from all patients in the AQP4Ab1
NMOSD group and absent in all other groups. MOG-Abs were
not detected in any serum samples. Demographics, clinical data,
and treatments of the different groups are summarized in
table 1.
Microarray staining and reading. Peptide arrays were carried
out as previously described in detail (appendix e-1 at Neurology.
org/nn). In setup experiments, a prestaining with the secondary
DyLight 549 conjugated goat anti-human immunoglobulin G
(IgG) antibody (diluted 1:1,000 in staining buffer; incubation
for 30 minutes; anti-human IgG [H&L] goat antibody;
Rockland, Gilbertsville, PA) was performed and showed that all
background interactions were negligible compared to subsequent
serologic assays. The arrays were then incubated overnight with
serum samples diluted 1:1,000 in staining buffer (phosphate-
buffered saline, pH 7.4, 0.05% Tween 20 with 10% Rockland
Blocking Buffer MB-070). Next, the DyLight 549 conjugated
goat anti-human IgG was used as secondary antibody.
Microarrays were read with a Fujifilm Life Science (Stamford,
CT) FLA-5100 imaging system using a second harmonic
generation 532 nm (green) diode laser and a LPG filter. HA
and FLAG epitopes were printed on the microarrays in a square
surrounding the other peptides and stained in a final step with the
corresponding antibodies (mouse anti-HA-Cy5 11801; mouse
anti-FLAG M2-Cy3 11802; provided by PEPperPRINT,
Heidelberg, Germany). An example of a stained microarray is
given in figure e-1. Quantification of spot intensities and
peptide annotation were done with PepSlide Analyzer
(PEPperPRINT). Results are expressed as fluorescence intensity
units, which reflect the extent of antibody binding to the selected
peptides.
Peptide microarrays. Three different types of peptide microar-
rays were used: antigen microarray, mimotope microarray, and
selection microarray. Peptide microarrays were produced with
an innovative method using a peptide laser printer and amino
acid particles for a combinatorial synthesis of peptides
(PEPperPRINT).15 All peptide probes were printed in duplicates
on the array. In a first step, the antigen and mimotope microarrays
were incubated with 6 different pools of sera (5 pools of patient
sera, 1 pool of healthy controls) for a preselection of reactive
peptides. In a second step, selection microarrays were printed with
the selected peptides. These selection microarrays were used for
screening for peptide antibody reactivities in the sera from the 66
patients and controls.
Antigen microarray. Based on a literature search, we com-
posed a set of 46 (auto) antigens of potential relevance for the
pathology of inflammatory demyelinating diseases (table e-1).
The full-length amino acid sequences of these antigens were
synthesized as 15-mer peptides (offset 5, overlap 10 amino acids),
resulting in a peptide microarray containing a total of 4,418
different peptide probes.
Mimotope microarray. Additionally, 4,290 15-mer random
peptides (mimotopes) were generated by a computer algorithm
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and printed on a microarray (PepSlide Designer; Sicasys GmbH,
Heidelberg, Germany).
Selection microarray. Based on peptide reactivities identi-
fied in the screening with the antigen and mimotope microarray
and including peptides of special interest as well as control pepti-
des, 702 peptides were selected for the selection microarray (see
Results and table e-2). This selection microarray was used to ana-
lyze whether different peptide antibody reactivities may distin-
guish between AQP4Ab1 and AQP4Ab2 NMOSD as well as
RRMS.
Statistics and bioinformatic analysis. Statistical analysis of
the microarray data was performed with R statistical computing
software (version 3.1.2; www.r-project.org). Median signal
intensities were log2 transformed and the means between the 2
replicate spots of the same peptide were calculated. Correlation
between replicate spots was used as a quality control. To reduce
technical variability between the different measurements of
patient sera, a normalization was performed by subtracting the
average of all 39 control peptides per patient from each
measurement (normalized intensity 5 log2 signal to noise
ratio). Peptides with either consistently high or consistently low
reactivities in the antigen and mimotope microarrays were
selected as controls (see list in table e-2). Three peptides were
excluded due to cross-reactivities with anti-HA antibodies used to
stain control peptides. To test for pairwise differences among
AQP4Ab1 NMOSD, AQP4Ab2 NMOSD, RRMS, and
controls, the R package limma was used, an empirical Bayes
method for the analysis of microarray data using linear models
for the assessment of differential expression.16 For the analyses,
only noncontrol peptides were used to which at least 5% of the
study participants had normalized intensity measurements greater
than log2(1,000). p Values were adjusted for multiple hypothesis
testing using the method of Benjamini and Hochberg to control
for a false discovery rate. Peptides found to be most significant by
limma as well as AQP4 peptides were visualized in a heat map
from the R package gplots to further classify subgroups of
patients. For this, individual peptide data were standardized
using z scores (i.e., x2m/s) based on the data from the healthy
controls. To focus on groups of peptides instead of individual
peptides, we used global tests from the R package
RepeatedHiDim17 to test for significant interactions, while
main effects in mean expression of the groups were evaluated
by the Welch test. MA plots (i.e., Bland-Altman plots) were
used to visualize differential peptide reactivities between pairs of
patient groups. Classification of patient groups based on the
peptide reactivities was performed using nearest shrunken
centroids with the R package PAMR. PAMR uses an internal
feature selection and 10-fold cross-validation.18 Significance
thresholds were set at 5%.
RESULTS A customized microarray for inflammatory
demyelinating CNS diseases. To set up a customized
microarray for inflammatory demyelinating diseases
(selection microarray), we first screened 8,708 pepti-
des represented on the antigen and mimotope micro-
arrays for differential peptide reactivities with 6 pools
Table 1 Demographic and clinical data
Antigen and mimotope array
AQP4Ab1 NMOSD
(n 5 4)
AQP4Ab2 NMOSD
(n 5 4)
Immunopattern I
(n 5 4)
Immunopattern II
(n 5 4)
Immunopattern III
(n 5 4)
Healthy controls
(n 5 4)
Age, y, median (range) 38.5 (18–64) 45.5 (30–66) 43.5 (16–48) 34.5 (11–54) 45 (34–53) 39 (27–49)
F/M 3/1 2/2 2/2 2/2 3/1 2/2
TM 1 ON, n 4 4 NA NA NA NA
Isolated TM, n 0 0 NA NA NA NA
Isolated ON, n 0 0 NA NA NA NA
Disease duration, mo,
median (range)
16.5 (1.5–24) 9.5 (4–34) 10 (4–72) 15 (4–42) 42 (4–108) NA
EDSS, median (range) 8.3 (1.5–9.0) 3.7 (2.5–6.0) 2.8 (1.0–3.5) 3.5 (2.0–4.5) 3.5 (2.5–7.5) NA
Therapy, no. Aza 2; none 2 Aza 3; none 1 IFN-b 2; GA 1; none 1 IFN-b 2; none 2 Rituximab 1; HDCS 1
mitoxantrone 1; none 2
NA
Selection microarray AQP4Ab1 NMOSD (n 5 16) AQP4Ab2 NMOSD (n 5 19) RRMS (n 5 11)
Healthy controls
(n 5 20)
Age, y, median (range) 46.5 (18–75) 46 (27–72) 31 (23–54) 36 (21–80)
F/M 15/1 13/6 8/3 16/4
TM 1 ON, n 12 8 NA NA
Isolated TM, n 2 11 NA NA
Isolated ON, n 2 0 NA NA
Disease duration, mo, median (range) 57 (21–336) 21 (1–280) 11 (2–36) NA
EDSS, median (range) 3.5 (1.5–6.5) 2.5 (1.5–8)a 1.5 (0–4) NA
Therapy, n Aza 7; MTX 1; rituximab 7;
MMF 1 steroids 1
Aza 4; cyclophosphamide 1;
mitoxantrone 1; rituximab 3;
oral steroids 2; none 8
IFN-b 4; GA 2; none 5 NA
Abbreviations: AQP4Ab 5 aquaporin-4 antibody; Aza 5 azathioprine; EDSS 5 Expanded Disability Status Scale; GA 5 glatiramer acetate; HDCS 5 high-
dose corticosteroids; IFN 5 interferon; MMF 5 mycophenolate mofetil; MTX 5 methotrexate; NA 5 not applicable; NMOSD 5 neuromyelitis optica spec-
trum disorders; ON 5 optic neuritis; RRMS 5 relapsing-remitting multiple sclerosis; TM 5 transverse myelitis.
a Data available from 17 patients.
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of serum samples of AQP4Ab2 NMOSD,
AQP4Ab1 NMOSD, MS with histopathologically
defined immunopatterns of demyelination I, II, and
III,10 or controls. Based on the results of this screening,
439 peptides were selected according to one of the
following criteria (table e-2A): peptides showed differ-
ential binding in any of the pairwise comparisons
between serum pools (.2-fold and intensity .2,048
arbitrary intensity units) or peptides had very high
reactivity in at least one serum pool (intensity
.4,096 arbitrary intensity units). Furthermore, 39
control peptides and 224 peptides of special interest
(Epstein-Barr nuclear antigen-1 [EBNA-1] peptides;
viral peptides with reactivities .1,024 arbitrary
intensity units; selected AQP4, AQP1, MOG, and
KIR4.1 peptides; and peptides with differential
binding of MS immunopatterns as published by
Quintana et al.8) were assembled on the microarray.
A list of all 702 peptides is provided in table e-2B.
Differential peptide antibody reactivities are most
frequent in RRMS. For identification of peptide anti-
body reactivities that may distinguish among
AQP4Ab1 and AQPAb2 NMOSD, RRMS, and
controls, we screened a total of 66 sera from those 4
groups with the selection microarray. To select for
robust peptide reactivities, we included only those
225 peptides in the further pairwise comparisons to
which at least 5% of study participants had normalized
intensity values greater than log2(1,000) (see Statistics
and bioinformatic analysis; complete list of results in
table e-3). We report differentially bound peptides with
a p value ,0.05 with peptides remaining significant
after adjustment for multiple testing given in brackets.
The highest number of differentially bound peptides
were found in the comparisons of RRMS with
AQP4Ab1 NMOSD (n 5 69 [34]), controls (n 5
60 [16]), or AQP4Ab2 NMOSD (n 5 46 [22]).
Lower numbers of differentially bound peptides were
evident in comparisons between the 2 NMOSD sub-
groups (n 5 13 [0]) and between controls and
AQP4Ab1 NMOSD (n 5 9 [0]) or AQP4Ab2
NMOSD (n 5 19 [0]). When comparing all patients
with NMOSDwith patients with RRMS, we identified
66 (33) differentially bound peptides.
Antibody reactivities to the majority of differen-
tially bound peptides were higher in patients with
RRMS and included Epstein-Barr virus (EBV) pepti-
des, myelin peptides (PLP, MAG), oligodendrocytic
peptides (NOGO-A, AN-2), astrocytic peptides
(AQP4, S100b), axonal/neuronal peptides (neurofas-
cin, neurofilament, contactin-2), and several mimo-
topes. Peptides derived from type 1 interferon,
amyloid-b, hypoxia-inducible factor 1-a, transferrin
receptor protein 1, and chitinase-3-like protein 1 also
showed higher reactivities.
AQP4Ab1 NMOSD sera did not show higher
reactivities to AQP4 peptides than AQP4Ab2
NMOSD sera when analyzing individual AQP4
peptides.
Antibody signatures differentiate patient subgroups. We
generated heat maps to compare multiple antibody
reactivities (antibody signatures) between the differ-
ent patient groups. The 68 peptides used in this anal-
ysis comprised of the 20 most significant peptides
from each pairwise subgroup comparison (table e-3)
as well as an additional 4 AQP4 peptides that were
detected in at least 5% of study participants with nor-
malized intensity measurements above log2(1,000)
(figure 1). Numerous reactivities against single pep-
tides were higher in patients than in controls, and
reached up to 5 standard deviations, indicating clear
increases in antibody reactivities. Heat maps showed a
clustering of RRMS and AQP4Ab1 NMOSD (fig-
ure 1A), indicating different antibody signatures in
these patient groups. Such a clustering was also seen
in RRMS compared to AQP4Ab– NMOSD (figure
1B). However, antibody signatures did not clearly
separate the 2 NMOSD subgroups (figure 1C).
Elevated reactivities to myelin and EBV peptides in
RRMS. In the next step, groups of related peptides,
rather than individual peptides, were compared
between AQP4Ab1NMOSD, AQP4Ab2NMOSD,
and RRMS. All peptides that belonged to one protein
(e.g., AQP1, AQP4, NOGO-A), a certain virus (EBV,
cytomegalovirus, varicella-zoster virus), or a group of
proteins (all myelin proteins) were combined. For this
analysis, we report all highly significant differences in
group comparisons (p # 0.01).
Patients with RRMS showed higher reactivities
against myelin peptides than patients with AQP4Ab1
NMOSD (p 5 0.003) and patients with AQP4Ab2
NMOSD (p 5 0.0002) (figure 2, A and B). Myelin
peptide reactivities were increased at most to approxi-
mately 150% in patients with RRMS compared to
patients with AQP4Ab1 NMOSD and to 133%
compared to patients with AQP4Ab2 NMOSD. Val-
ues on the x-axis in figure 2, A–D, represent the aver-
age reactivities of peptides for the investigated groups.
Higher antibody reactivities to EBV peptides were
observed in RRMS than in AQP4Ab1 NMOSD
(p5 0.0012). Such a difference was not evident when
comparing patients with RRMS with patients with
AQP4Ab2 NMOSD (p 5 0.1097). Reactivities
against EBV peptides in RRMS were up to 230%
of those found in AQP4Ab1 NMOSD (figure 2C).
Elevated reactivities to AQP4 and AQP1 peptides in
AQP4Ab1 NMOSD. We next analyzed antibody reac-
tivities to the group of AQP4 peptides in the 2
NMOSD subgroups. Although single AQP4 peptides
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had not shown significant differences in antibody
binding, group comparisons demonstrated higher
AQP4 peptide reactivities in AQP4Ab1 NMOSD
than in AQP4Ab2 NMOSD (p 5 0.0001) (figure
2D). Reactivities of AQP4Ab1 NMOSD increased
at most to approximately 133%. Patients with
AQP4Ab1 NMOSD also showed higher reactivities
than patients with RRMS (p 5 0.0110). In addition,
higher reactivities against AQP1 peptides were found
in the AQP4Ab1 NMOSD group compared to
AQP4Ab2 NMOSD (p 5 0.0052).
Correct patient subgroup classification by peptide
reactivities is expected in 61%–81%.We tested whether
antibody signatures permit subgroup classification
into AQP4Ab1 and AQP4Ab2 NMOSD as well
as RRMS. The predicted correct subgroup classifica-
tion was 78% for the differentiation of AQP4Ab1
NMOSD and RRMS and 80% for the differentiation
of AQP4Ab2 NMOSD and RRMS. Differentiation
of subgroups was based on 17 (AQP4Ab1 NMOSD
vs RRMS) or 33 peptides (AQP4Ab2 NMOSD and
RRMS). In contrast, the predicted correct subgroup
classification based on 70 peptides was only 66% for
the comparison between AQP4Ab1 and AQP4Ab2
NMOSD and based on 33 peptides 61% for the
comparison of all NMOSD vs RRMS.
DISCUSSION We report a systematic serum anti-
body screening in patients with NMOSD with and
without AQP4-Abs, in patients with RRMS, and in
Figure 1 Neuromyelitis optica spectrum disorder (NMOSD) subgroups and patients with relapsing-remitting
multiple sclerosis (RRMS) show different antibody signatures
Heat maps (A: RRMS [blue] vs aquaporin-4 antibody [AQP4Ab]1 NMOSD [red]; B: RRMS [blue] vs AQP4Ab2 NMOSD [pur-
ple]; C: AQP4Ab1 NMOSD [red] vs AQP4Ab2 NMOSD [purple]). The top 20 peptides from all pairwise subgroup compar-
isons as well as all AQP4 peptides are shown as rows (see key for peptides). Patients from the different subgroups are
shown as columns (see key for patient groups). The color (see key for z score) indicates the intensity of the peptides
standardized to the healthy controls, with blue indicating an upregulation and red a downregulation of peptide reactivities,
given in standard deviations. Heat maps show a clustering of RRMS and AQP4Ab1 NMOSD (A) as well as RRMS and
AQP4Ab2 NMOSD (B), suggesting different antibody signatures in these patient groups. In contrast, such a clustering is
not evident comparing the 2 NMOSD subgroups (C). CMV 5 cytomegalovirus; EBV 5 Epstein-Barr virus; VZV 5 varicella-
zoster virus.
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healthy controls, employing a customized peptide
microarray specifically designed for inflammatory
demyelinating CNS diseases. The key results of this
study are that NMOSD and RRMS show
differential antibody reactivities to a number of
human and viral antigens as well as to random
Figure 2 Elevated antibody reactivities against myelin and Epstein-Barr virus (EBV) peptides in relapsing-
remitting multiple sclerosis (RRMS) and higher anti–aquaporin-4 (AQP4) peptide reactivities in
neuromyelitis optica spectrum disorders positive for AQP42Abs (AQP4Ab1 NMOSD)
Comparison of selected peptide groups in different patient subsets shown with MA plots. (A) Myelin peptides RRMS vs
AQP4Ab1 NMOSD. (B) Myelin peptides RRMS vs AQP4Ab2 NMOSD. (C) EBV peptides RRMS vs AQP4Ab1 NMOSD. (D)
AQP4 peptides AQP4Ab1 vs AQP4Ab2 NMOSD. Each dot represents one peptide. The x-axis displays the average nor-
malized signal to show the general level of peptide binding. The y-axis indicates the difference between the patient groups
given as a percentage. Greater reactivities in the first mentioned group are found above the 100%horizontal line, and lower
reactivities below this line. Patients with RRMS show higher antibody reactivities against myelin peptides and EBV-EBNA
1 peptides than do patients with NMOSD. Higher antibody reactivities against AQP4 peptides are evident in the AQP4Ab1
compared to the AQP4Ab2 NMOSD group.
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peptides (mimotopes), and that based on these
antibody reactivities a correct patient subgroup
classification to distinguish RRMS and NMOSD can
be achieved in approximately 80% of patients.
However, NMOSD subgroups, although clearly
differentiated by the positivity or negativity for
AQP4-Abs in cell-based assays, are not well
discriminated by multiple peptide antibody reactivities.
Transfer of AQP4-Abs to animals produces
NMO-like lesions, indicating that AQP4-Abs are
pathogenic.19–21 The detection of AQP4-Abs by
cell-based assays transfected with full-length, confor-
mational AQP4 protein represents the diagnostic gold
standard for the diagnosis of AQP4Ab1 NMOSD
with a higher sensitivity in the detection of anti-
AQP4-Abs compared to peptide-based assays.22 Sev-
eral studies reported antibodies against linear AQP4
peptides,23,24 showing that antibody reactivities
directed against AQP4 peptides can be detected using
peptide microarrays. Consistent with this, we
observed higher reactivities to the group of AQP4
peptides in AQP4Ab1 vs AQP4Ab2 NMOSD.
However, when comparing antibody reactivities to
single AQP4 peptides between patients with
AQP4Ab1 vs AQP4Ab2 NMOSD and patients
with RRMS, we were unable to identify specific re-
activities, and thus no specific epitopes within the
AQP4 protein that were preferentially targeted by
AQP4-Abs were detected. Interestingly, we found
higher reactivities to AQP1 peptides in the
AQP4Ab1 NMOSD group compared to the
AQP4Ab2 NMOSD group. Whether the water
channel AQP1 may be an additional autoimmune
target in patients with NMOSD is a matter of
controversy.25,26
A total of 20%–40% of patients showing typical
NMOSD clinical symptoms do not have AQP4-Abs
according to the applied assay,4 and only some of
these patients have MOG-Abs.27 Our results showed
that antibody signatures of AQP4Ab1 and
AQP4Ab2 NMOSD are more similar, but can be
well-differentiated from RRMS. Although studies
based on a small number of samples suggested that
AQP4Ab1 and AQP4Ab2 NMOSD do not share
the same pathophysiology,19,28 other in vitro studies
showed that sera from AQP4Ab2 patients induced
complement-dependent astrocyte cell death, as did
AQP4Ab1 sera, although to a lower extent.29 One
explanation could be that patients with AQP4Ab2
NMOSD do indeed have AQP4-Abs that are unde-
tectable even by highly sensitive cell-based assays.
Thus, we cannot rule out the possibility of a false
assignment of true seropositives to the seronegative
group. Another possibility would be that other not
yet identified antibodies acting in a manner similar to
AQP4-Abs (e.g., targeting astrocytes) could play a
pathogenetic role. Finally, a T-B-cell cooperation is
necessary in NMO lesion formation30,31 and the role
of T-cell pathogenicity may differ between
AQP4Ab1 and AQP4Ab2 NMOSD.
With optimized autoantibody detection, a mean
sensitivity for AQP4-Ab detection of 76.7% is
found.2 Thus, compared to the AQP4-Ab testing
with cell-based assays, the selection microarray anal-
ysis might not to be helpful for differentiating
NMOSD in general (including AQP41 NMOSD)
from RRMS, yet may be beneficial for patients with
NMOSD without AQP4-Abs, with a predicted cor-
rect subgroup classification of 80%. Future studies
may thus concentrate on evaluating peptide antibody
reactivities for the differentiation of AQP4-Ab-negative
NMOSD and MS.
EBV is a risk factor for MS, and EBV seropreva-
lence in patients with MS reaches nearly 100%. Pa-
tients with MS are known to have an elevated
antibody response to EBV proteins and peptides.32,33
Significantly higher anti-EBNA-1 IgG antibody titers
in patients with MS than in patients with NMOSD
were found,34 which is in line with our results. In
addition, patients with RRMS had higher anti-
myelin peptide reactivities than patients in both
NMOSD subgroups. The suspected antigenic target
in MS is the oligodendrocyte/myelin unit and not the
astrocyte as in NMOSD. Antibody reactivities against
myelin proteins in MS have been studied exten-
sively,35 but the specificity and pathogenicity of these
antibodies is unclear. MOG-Abs have been associated
with clinical syndromes of AQP42 NMOSD, acute
disseminated encephalomyelitis, and MS5 and it is
suggested that MOG-Ab-associated diseases may rep-
resent a separate disease entity.36,37 For this reason,
patients with MOG-Abs as measured in cell-based
assays were excluded in this work.
A limitation of our study is the small number of
participants in each group. Our results are therefore
preliminary and need confirmation with larger and
independent patient cohorts. In addition, we cannot
rule out that prior immunosuppressive/immunomod-
ulatory treatment might have influenced the results.
However, we employed strict criteria for allotting pa-
tients to the different patient groups and controlled
for multiple testing. Our peptide microarray contains
linear but not conformational epitopes. It is assumed
that successful identification of pathogenic autoanti-
bodies relies on expression systems that display con-
formational epitopes with all modifications that
occur in vivo.38 Nonetheless, antibody reactivities
against peptides, although with a lower frequency,
may also be detectable in diseases in which antibodies
against conformational epitopes are thought to be
pathogenic, as shown for AQP4 antibodies.23,24 In
addition, peptides may also induce autoimmune
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disease, as is evidenced by the induction of experi-
mental allergic encephalomyelitis, an experimental
model of MS, with MOG peptides. Finally, although
it is unlikely that it will be possible to detect single
pathogenic autoantibodies using our approach, the
peptide microarray technique has the advantage of
analyzing multiple antibody reactivities involved in auto-
immune diseases. Antigen arrays have been used success-
fully in autoimmune diseases for disease diagnosis,
monitoring of disease progression and response to ther-
apy, and discovering mechanisms of pathogenesis.39,40
Our results revealed antibody signatures that may be a
valuable tool in differentiating NMOSD and RRMS.
Future research should focus on reproducing the
results in different cohorts and may also be applied
to patients with RRMS stratified according to their
histopathologic characteristics.10 Different peptide
antibody signatures have been shown previously in
different MS stages and histologically classified MS,8
results that we extended by showing that differential
antibody signatures might distinguish NMOSD and
RRMS. Better diagnostic tools in inflammatory
demyelinating diseases are an important basis for
targeted and individualized patient care.
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